Exploring Optimal Parameters for Ligand-Based Virtual Screening in Early Drug Discovery
Temitope Sobodu, Victor Chibuzor Johnson, Ryan Kern, Peter Oni
q-bio.BM
Quick verdict
Ligand-based VS parameter study on 4 aminergic ligands: transparent and honestly analyzed, but optimality rests on proxy endpoints without activity validation.
Summary
This study asks whether common parameter choices in ligand-based virtual screening—Tanimoto cutoff, extended-connectivity fingerprint setting, and atom-invariant scheme—can be standardized, using four aminergic drugs (atomoxetine, bupropion, mirtazapine, venlafaxine) to query the Enamine make-on-demand library via SpaceMACS (top 10,000 per query). Retrieved sets were scored on compound-weighted WIPO scaffold novelty, normalized Shannon scaffold diversity, and a composite of SA score, RAscore and SCScore, combined through Pareto filtering and equal-weight utility, with 5,000 random weightings for sensitivity. No single Tanimoto cutoff fit all ligands (optima 0.224–0.415; three at the retrieval boundary). ECFP8 was the most stable pooled setting (74.1% winner share), but a strong setting-by-ligand interaction (F12,79=18.05, partial η²=0.733) left venlafaxine favoring ECFP2 (88.8%). ECFP4 beat FCSFP4 as primary fingerprint (91.5% pooled winner share) while FCSFP4 retrieved largely nonredundant space (compound overlap 10.3–47.2%). Against 240 blinded ratings (229 unique structures) from three chemists, SCScore correlated best with the consensus (Spearman 0.591); leave-one-ligand-out calibration gave negative R² for mirtazapine and venlafaxine, so scores serve as triage only. Main limitations: only four aminergic ligands, no biological-activity validation, and optimality defined purely by proxy objectives.
Review complete
Assessment at a glance
5
risk flags identified
● high 0
● medium 3
● low 2
5 strengths · 5 weaknesses · 5 author questions
AI text signal = Binoculars zero-shot detector score over 20 sampled passages (Fast-DetectGPT co-reported) — absence does not prove human authorship, and a flag does not imply misconduct.
Levels reflect verification complexity — not a quality score. Evolve never rates your paper.
Key claims under review
- No single Tanimoto cutoff balances novelty, diversity and synthesis across the four ECFP4 searches; operating points are ligand-specific (0.265, 0.415, 0.224, 0.324; Table 1).
- ECFP8 is the most stable pooled fingerprint setting (74.1% of 5,000 random priority weightings; Pareto-efficient in 95% of strata), but a large setting-by-ligand interaction (F12,79=18.05, partial η²=0.733) means venlafaxine consistently favors ECFP2 (88.8%).
- ECFP4 is the stronger primary fingerprint over FCSFP4 (91.5% pooled winner share; novelty higher in 17/20 matched pairs), yet FCSFP4 adds largely nonredundant compounds and scaffolds (top-10,000 compound overlap 10.3–47.2%).
- SCScore agrees best with a blinded three-chemist consensus (pooled Spearman 0.591 on 229 structures), but leave-one-ligand-out calibration yields negative R² for mirtazapine and venlafaxine, so computational scores are triage, not transferable replacements for expert review.
Strengths
Honest treatment of dependent data
Nested cumulative top-N sets are explicitly declared non-independent (§4.6); regression F-tests (Table 2) and Wilcoxon P values (Table 3) are labeled descriptive, with decisions anchored on Pareto efficiency, mean utility ranks (ECFP8: 2.15 vs ECFP2: 2.80) and 5,000 Dirichlet weightings with Monte Carlo SE (max 0.71 pp).
Blinded external benchmark with quantified reliability
Three chemists rated 240 records blind to algorithmic scores; single-vs-mean-rater reliability gain is reported (ICC(2,1)=0.358 → ICC(2,3)=0.625; Kendall's W=0.556), with within-rater repeat SDs (0.050–0.091) justifying a panel consensus.
Transferability is tested, not assumed
Threshold identifiability is quantified
Reproducibility provisions
Weaknesses
Optimality defined only by proxy objectives
Tiny, homogeneous query set vs. broad title
Fingerprint provenance ambiguity
Thinly described expert benchmark
No uncertainty on headline validation numbers
Full Review Report
$1.99 · one-timeUnlock the complete preliminary analysis Evolve produced for this paper.
Report preview
Preliminary Review: Exploring Optimal Parameters for Ligand-Based Virtual Screening in Early Drug Discovery (arXiv:2609.16356)
The remaining sections cover Methodology Assessment, Statistical Evidence, Results & Reproducibility, Limitations & Risks, and Verdict & Recommendations.
- All 5 strengths & 5 weaknesses, analyzed in detail
- 5 risk flags with severity, section & reviewer questions
- Methods & statistical evidence assessment
- 5 questions a peer reviewer would ask
- Full six-dimension evaluation report & recommendations
One-time purchase · this paper only
One-time purchase, this paper only. AI-generated preliminary analysis — not peer review.
Frequently asked questions
What is the best ECFP fingerprint setting for ligand-based virtual screening?
According to this study, ECFP8 was the most stable pooled choice across four aminergic query drugs (selected in 74.1% of 5,000 random priority weightings). However, the best setting was ligand-dependent: venlafaxine consistently favored ECFP2 (88.8%), and the setting-by-ligand interaction explained most utility variation (partial η²=0.733). The authors recommend ECFP8 as a starting default followed by per-ligand calibration.
Which synthetic accessibility score best matches expert chemist judgment?
In this paper, SCScore agreed best with a blinded three-chemist consensus (pooled Spearman 0.591 on 229 unique structures; AUROC 0.728 for the hardest and 0.852 for the easiest difficulty quartile), while a three-score composite gave the best hardest-quartile AUROC (0.750). Agreement was ligand-dependent — near zero for mirtazapine — and out-of-sample calibration failed for two of four ligand series, so the scores are recommended for triage only.
Is there a universal Tanimoto similarity cutoff for virtual screening?
No. The study found ligand-specific optima (0.265, 0.415, 0.224, 0.324 with ECFP4 across four drugs), three of which sat at the broadest retrieval boundary tested, and recommends reporting operating intervals together with retained-set sizes rather than a single universal cutoff.
Did this study test any compounds experimentally?
No. It measured the composition of retrieved virtual screening sets (scaffold novelty vs patent annotation, scaffold diversity, predicted synthetic accessibility) and compared computational scores with blinded chemist difficulty ratings. No synthesis, yield measurement or biological activity testing was performed.
About this review
This is an AI-generated preliminary review by Evolve.Pub, produced from the openly available text of the paper. It is not peer review and does not represent the authors' views. The canonical record of the paper is at the publisher link above.
- Figures are available only as captions; panel-level claims (Fig. 3 response-surface shapes, Fig. 4 profiles, TMAP structure) could not be verified from the text.
- The GitHub repository and interactive TMAP were not inspected; availability statements are taken at face value.
- Enamine records are commercial; all numeric checks rely on the reported summary statistics.
- Construction of the 240-record audit set (sampling scheme) is not described in the extracted text.
Go deeper on this paper
Wrote a paper? Stress-test it before reviewers do.
Upload your manuscript for the same structured scrutiny — reasoning, statistics, evidence, figures, and reproducibility.